The global molecular quality control market was valued at USD 1.082 billion in 2025. The market is estimated at USD 1.171 billion in 2026 and is projected to reach USD 2.564 billion by 2036, at a CAGR of 8.2% during the forecast period 2026-2036. This report assesses control technologies, kit versus independent controls, quality control practice by laboratory setting, the value chain, regulation and accreditation, cost per determination, the competitive landscape, and future growth opportunities.
The market covers the control materials, calibrators, panels, and software that laboratories and assay makers rely on to confirm that molecular tests perform as intended. It includes independent third-party controls, instrument- and assay-specific controls, quantitative calibrators and standards, multi-analyte and syndromic panels, whole-process controls in swab, plasma, or other matrices that test extraction as well as amplification, and software for quality control review and peer-group comparison. Non-molecular controls, sequencing development reference materials, external quality assessment schemes, assay kits, and instruments are excluded.
Because each analytical run needs controls, demand recurs and rises with the number of runs and assays rather than only with instrument sales. In December 2024, revised Clinical Laboratory Improvement Amendments (CLIA) requirements came into force, and the College of American Pathologists updated its accreditation checklists to match, and the FDA final rule on laboratory developed tests was vacated by a federal court in March 2025, leaving laboratories responsible for proving ongoing assay performance under CLIA and accreditation. In Europe, the In Vitro Diagnostic Regulation required manufacturers of Class C self-declared legacy devices to sign an agreement with a notified body by September 26, 2026, raising demand for traceable controls. Testing growth also adds demand, with Tempus AI reporting 31% growth in oncology testing volume in the second quarter of 2026.
The use of leftover patient samples or pooled in-house material in place of commercial controls restrains the market, since these behave like real specimens and cost little, although such material is limited and rarely covers every multiplex target. Cost pressure is a further restraint, as controls produce no billable result and strained laboratories may run them only at the minimum frequency, use narrower panels, or stretch each vial; Bio-Rad has also pointed to continuing weakness in academic research spending. Key challenges include commutability, as manufactured controls can differ from clinical samples in nucleic acid packaging, fragmentation, matrix, and inhibitors, and keeping control panels current as manufacturers add targets and new pathogens or variants emerge.
Independent third-party and whole-process controls offer a major opportunity, along with low-level controls for molecular oncology and liquid biopsy, quality control data management and peer-group reporting, which gain value as more laboratories take part, and regulatory-grade controls for diagnostic manufacturers and European markets. Key trends include the shift from kit-supplied controls to independent controls, consolidation of the supplier base through acquisitions, and the bundling of controls with data management and peer comparison services.
By product, the molecular quality control market is segmented into independent third-party controls (whole-process controls in matrix, multi-analyte & syndromic panels, and single-analyte controls), instrument- & assay-specific controls, calibrators & quantitative standards, and quality control data management software. In 2026, independent third-party controls are expected to hold the largest share, and they are also set to grow at the highest CAGR during the forecast period, as laboratories and accreditation bodies prefer controls that do not come from the assay maker, independent controls can expose systematic faults that kit controls may miss, laboratories running several platforms need consistent cross-platform comparison, and multi-analyte panels and whole-process formats are expanding within this segment. Quality control software is also set for strong growth as laboratories adopt statistical review and peer comparison.
By analyte type, the molecular quality control market is segmented into viral controls (respiratory viruses, blood-borne viruses, and other viruses), bacterial controls, human genomic & somatic variant controls, fungal & parasitic controls, and other controls. In 2026, viral controls are expected to account for the largest share, reflecting high testing volumes for respiratory and blood-borne viruses and sexually transmitted infections, viral load monitoring that uses both controls and calibrators, and the many viral targets on syndromic panels. Human genomic & somatic variant controls are projected to record the highest CAGR, as cancer, liquid biopsy, inherited disease, and drug-response testing expand and require controls that prove detection at low allele frequencies.
By technology, the molecular quality control market is segmented into polymerase chain reaction (real-time PCR and digital PCR), next-generation sequencing, isothermal & other amplification methods, and hybridization & other technologies. In 2026, polymerase chain reaction is expected to hold the largest share, as real-time PCR is the main method in clinical molecular diagnostics, PCR runs are performed in very large numbers worldwide, and controls must accompany each run or be run at set intervals. Next-generation sequencing is projected to grow at the highest CAGR, supported by more clinical sequencing in oncology and inherited disease, complex workflows that need controls for library preparation and bioinformatics, and a growing installed base of sequencers.
By application, the molecular quality control market is segmented into infectious disease testing (respiratory, sexually transmitted, gastrointestinal, and other infections), oncology testing, genetic & inherited disease testing, blood & plasma screening, and other applications such as transplant monitoring and pharmacogenomics. Infectious disease testing is expected to account for the largest share in 2026, because molecular infectious disease volumes remain above pre-pandemic levels, syndromic panels are widely used, and running independent controls is established practice in this field. Oncology testing is projected to record the highest CAGR, as comprehensive genomic profiling, liquid biopsy, and residual disease testing expand and need controls at low variant allele frequencies.
By end user, the molecular quality control market is segmented into hospital & clinical laboratories, reference & commercial laboratories, public health & government laboratories, blood & plasma screening centers, and in vitro diagnostic manufacturers & other end users. Hospital & clinical laboratories are expected to account for the largest share in 2026, given the number of hospital laboratories running molecular tests, their duty to keep a documented control program for each assay, and the move of testing into hospital and satellite sites. In vitro diagnostic manufacturers & other end users are projected to grow at the highest CAGR, as assay development, verification, and lot release use large quantities of control material and the European In Vitro Diagnostic Regulation requires documented characterization and traceability.
North America is expected to lead the global molecular quality control market in 2026, owing to the scale of molecular testing, CLIA and accreditation rules that require documented quality control programs, long-standing use of independent controls, and a strong base of suppliers such as Bio-Rad Laboratories, Streck, Thermo Fisher Scientific, ZeptoMetrix, Microbiologics, and Maine Molecular Quality Controls. Europe holds a significant position, supported by accreditation under international laboratory standards, high testing volumes, blood and plasma screening programs, and suppliers such as LGC Clinical Diagnostics, Randox Laboratories, and Qnostics, while the phased rollout of the In Vitro Diagnostic Regulation favors regulatory-grade controls.
Asia-Pacific is expected to be the fastest-growing region through 2036, driven by rapid additions to molecular testing capacity across China, India, Japan, and South Korea, wider adoption of international accreditation standards that bring formal control obligations, government spending on public health laboratory networks, and a stronger supplier presence in the region. Smaller shares are held by Latin America and the Middle East & Africa; molecular testing and accreditation growth support demand in Brazil and Mexico, while investment in clinical and public health laboratories and national disease programs supports growth in Saudi Arabia, the UAE, and South Africa.
The molecular quality control market is moderately consolidated, with dedicated control makers and diagnostics companies holding large positions alongside niche specialists and software providers. Companies compete on menu breadth, commutability, whole-process formats, lot-to-lot consistency, stability, regulatory grade, peer-group data, and price per determination. Leading players are matching menus to commercial panels, adding oncology controls, launching ready-to-use formats, and buying complementary portfolios. LGC acquired DiaMex of Heidelberg, Germany, in December 2024, adding its Optitrol serology and molecular controls, after earlier buying Technopath Clinical Diagnostics, while Bio-Rad acquired Exact Diagnostics and Cole-Parmer acquired ZeptoMetrix.
Key companies profiled in the report include LGC Limited (LGC Clinical Diagnostics) (U.K.), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Microbiologics, Inc. (U.S.), ZeptoMetrix LLC (Cole-Parmer) (U.S.), Maine Molecular Quality Controls, Inc. (U.S.), Randox Laboratories Ltd (U.K.), Revvity, Inc. (Horizon Discovery) (U.S.), Streck, Inc. (U.S.), and Qnostics Ltd (U.K.).
The market covers the control materials, calibrators, panels, and software that laboratories and assay makers rely on to confirm that molecular tests perform as intended. It includes independent third-party controls, instrument- and assay-specific controls, quantitative calibrators and standards, multi-analyte and syndromic panels, whole-process controls in swab, plasma, or other matrices that test extraction as well as amplification, and software for quality control review and peer-group comparison. Non-molecular controls, sequencing development reference materials, external quality assessment schemes, assay kits, and instruments are excluded.
Because each analytical run needs controls, demand recurs and rises with the number of runs and assays rather than only with instrument sales. In December 2024, revised Clinical Laboratory Improvement Amendments (CLIA) requirements came into force, and the College of American Pathologists updated its accreditation checklists to match, and the FDA final rule on laboratory developed tests was vacated by a federal court in March 2025, leaving laboratories responsible for proving ongoing assay performance under CLIA and accreditation. In Europe, the In Vitro Diagnostic Regulation required manufacturers of Class C self-declared legacy devices to sign an agreement with a notified body by September 26, 2026, raising demand for traceable controls. Testing growth also adds demand, with Tempus AI reporting 31% growth in oncology testing volume in the second quarter of 2026.
Market Dynamics
Wider molecular test menus and higher volumes are a major driver of the molecular quality control market, since every assay needs its own control strategy and every run needs controls. Molecular infectious disease testing is still far above pre-pandemic levels, oncology and genetic testing keep growing, and control purchases do not fall when the volume of one test declines. Accreditation and regulation turn quality control from good practice into a requirement, as laboratories must set control frequency and acceptance limits, investigate failures, and show records during inspection. Multiplex syndromic panels that detect fifteen or more targets from one specimen need matching multi-analyte controls, which sell at much higher prices than single-target products, and the spread of molecular testing to hospital, satellite, urgent care, and near-patient sites multiplies the number of independent quality control programs.The use of leftover patient samples or pooled in-house material in place of commercial controls restrains the market, since these behave like real specimens and cost little, although such material is limited and rarely covers every multiplex target. Cost pressure is a further restraint, as controls produce no billable result and strained laboratories may run them only at the minimum frequency, use narrower panels, or stretch each vial; Bio-Rad has also pointed to continuing weakness in academic research spending. Key challenges include commutability, as manufactured controls can differ from clinical samples in nucleic acid packaging, fragmentation, matrix, and inhibitors, and keeping control panels current as manufacturers add targets and new pathogens or variants emerge.
Independent third-party and whole-process controls offer a major opportunity, along with low-level controls for molecular oncology and liquid biopsy, quality control data management and peer-group reporting, which gain value as more laboratories take part, and regulatory-grade controls for diagnostic manufacturers and European markets. Key trends include the shift from kit-supplied controls to independent controls, consolidation of the supplier base through acquisitions, and the bundling of controls with data management and peer comparison services.
Segment Analysis
The report analyzes the market by product, analyte type, technology, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnerships, and investment.By product, the molecular quality control market is segmented into independent third-party controls (whole-process controls in matrix, multi-analyte & syndromic panels, and single-analyte controls), instrument- & assay-specific controls, calibrators & quantitative standards, and quality control data management software. In 2026, independent third-party controls are expected to hold the largest share, and they are also set to grow at the highest CAGR during the forecast period, as laboratories and accreditation bodies prefer controls that do not come from the assay maker, independent controls can expose systematic faults that kit controls may miss, laboratories running several platforms need consistent cross-platform comparison, and multi-analyte panels and whole-process formats are expanding within this segment. Quality control software is also set for strong growth as laboratories adopt statistical review and peer comparison.
By analyte type, the molecular quality control market is segmented into viral controls (respiratory viruses, blood-borne viruses, and other viruses), bacterial controls, human genomic & somatic variant controls, fungal & parasitic controls, and other controls. In 2026, viral controls are expected to account for the largest share, reflecting high testing volumes for respiratory and blood-borne viruses and sexually transmitted infections, viral load monitoring that uses both controls and calibrators, and the many viral targets on syndromic panels. Human genomic & somatic variant controls are projected to record the highest CAGR, as cancer, liquid biopsy, inherited disease, and drug-response testing expand and require controls that prove detection at low allele frequencies.
By technology, the molecular quality control market is segmented into polymerase chain reaction (real-time PCR and digital PCR), next-generation sequencing, isothermal & other amplification methods, and hybridization & other technologies. In 2026, polymerase chain reaction is expected to hold the largest share, as real-time PCR is the main method in clinical molecular diagnostics, PCR runs are performed in very large numbers worldwide, and controls must accompany each run or be run at set intervals. Next-generation sequencing is projected to grow at the highest CAGR, supported by more clinical sequencing in oncology and inherited disease, complex workflows that need controls for library preparation and bioinformatics, and a growing installed base of sequencers.
By application, the molecular quality control market is segmented into infectious disease testing (respiratory, sexually transmitted, gastrointestinal, and other infections), oncology testing, genetic & inherited disease testing, blood & plasma screening, and other applications such as transplant monitoring and pharmacogenomics. Infectious disease testing is expected to account for the largest share in 2026, because molecular infectious disease volumes remain above pre-pandemic levels, syndromic panels are widely used, and running independent controls is established practice in this field. Oncology testing is projected to record the highest CAGR, as comprehensive genomic profiling, liquid biopsy, and residual disease testing expand and need controls at low variant allele frequencies.
By end user, the molecular quality control market is segmented into hospital & clinical laboratories, reference & commercial laboratories, public health & government laboratories, blood & plasma screening centers, and in vitro diagnostic manufacturers & other end users. Hospital & clinical laboratories are expected to account for the largest share in 2026, given the number of hospital laboratories running molecular tests, their duty to keep a documented control program for each assay, and the move of testing into hospital and satellite sites. In vitro diagnostic manufacturers & other end users are projected to grow at the highest CAGR, as assay development, verification, and lot release use large quantities of control material and the European In Vitro Diagnostic Regulation requires documented characterization and traceability.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 18 countries and four rest-of-region groups. The regional analysis of the molecular quality control market considers molecular testing volumes, accreditation and regulatory requirements, supplier presence, and investment in clinical and public health laboratories.North America is expected to lead the global molecular quality control market in 2026, owing to the scale of molecular testing, CLIA and accreditation rules that require documented quality control programs, long-standing use of independent controls, and a strong base of suppliers such as Bio-Rad Laboratories, Streck, Thermo Fisher Scientific, ZeptoMetrix, Microbiologics, and Maine Molecular Quality Controls. Europe holds a significant position, supported by accreditation under international laboratory standards, high testing volumes, blood and plasma screening programs, and suppliers such as LGC Clinical Diagnostics, Randox Laboratories, and Qnostics, while the phased rollout of the In Vitro Diagnostic Regulation favors regulatory-grade controls.
Asia-Pacific is expected to be the fastest-growing region through 2036, driven by rapid additions to molecular testing capacity across China, India, Japan, and South Korea, wider adoption of international accreditation standards that bring formal control obligations, government spending on public health laboratory networks, and a stronger supplier presence in the region. Smaller shares are held by Latin America and the Middle East & Africa; molecular testing and accreditation growth support demand in Brazil and Mexico, while investment in clinical and public health laboratories and national disease programs supports growth in Saudi Arabia, the UAE, and South Africa.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share and rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, molecular quality control and wider product portfolios, strategic developments, and SWOT analyses.The molecular quality control market is moderately consolidated, with dedicated control makers and diagnostics companies holding large positions alongside niche specialists and software providers. Companies compete on menu breadth, commutability, whole-process formats, lot-to-lot consistency, stability, regulatory grade, peer-group data, and price per determination. Leading players are matching menus to commercial panels, adding oncology controls, launching ready-to-use formats, and buying complementary portfolios. LGC acquired DiaMex of Heidelberg, Germany, in December 2024, adding its Optitrol serology and molecular controls, after earlier buying Technopath Clinical Diagnostics, while Bio-Rad acquired Exact Diagnostics and Cole-Parmer acquired ZeptoMetrix.
Key companies profiled in the report include LGC Limited (LGC Clinical Diagnostics) (U.K.), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Microbiologics, Inc. (U.S.), ZeptoMetrix LLC (Cole-Parmer) (U.S.), Maine Molecular Quality Controls, Inc. (U.S.), Randox Laboratories Ltd (U.K.), Revvity, Inc. (Horizon Discovery) (U.S.), Streck, Inc. (U.S.), and Qnostics Ltd (U.K.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global molecular quality control market.
- Explains how testing volumes, accreditation rules, syndromic panels, and decentralized testing are driving demand for controls.
- Assesses the impact of CLIA and CAP requirements, U.S. laboratory developed test oversight, and the EU In Vitro Diagnostic Regulation.
- Identifies high-growth opportunities across product, analyte type, technology, application, end user, and region.
- Tracks the shift to independent and whole-process controls, oncology controls, and peer-group software.
- Benchmarks leading suppliers on product portfolios, acquisitions, and strategic developments.
- Supports product, pricing, acquisition, and market entry decisions for control makers, diagnostics companies, and investors.
Key Questions Answered
- How big is the global molecular quality control market today, and how will it grow through 2036?
- Why are laboratories moving from kit-supplied controls to independent third-party controls?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are accreditation changes, U.S. laboratory developed test oversight, and the EU In Vitro Diagnostic Regulation affecting demand?
- Which products, analyte types, technologies, applications, and end users will grow the fastest?
- How are whole-process controls and quality control software changing laboratory quality programs?
- How is supplier consolidation reshaping the competitive landscape?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading suppliers, and what strategies are they using to strengthen their position?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Molecular Quality Control Market Assessment, by Product
6. Molecular Quality Control Market Assessment, by Analyte Type
7. Molecular Quality Control Market Assessment, by Technology
8. Molecular Quality Control Market Assessment, by Application
9. Molecular Quality Control Market Assessment, by End User
10. Molecular Quality Control Market Assessment, by Geography
11. Competition Analysis
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- LGC Limited
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Microbiologics, Inc.
- ZeptoMetrix LLC
- Maine Molecular Quality Controls, Inc.
- Randox Laboratories Ltd
- Revvity, Inc.
- Streck, Inc.
- Qnostics Ltd
